Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Inhibrx Biosciences (INBX) Research & Development: 2023-2024

Historic Research & Development for Inhibrx Biosciences (INBX) over the last 2 years, with Dec 2024 value amounting to $203.7 million.

  • Inhibrx Biosciences' Research & Development fell 26.63% to $28.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $121.0 million, marking a year-over-year decrease of 52.05%. This contributed to the annual value of $203.7 million for FY2024, which is 6.32% up from last year.
  • Per Inhibrx Biosciences' latest filing, its Research & Development stood at $203.7 million for FY2024, which was up 6.32% from $191.6 million recorded in FY2023.
  • In the past 5 years, Inhibrx Biosciences' Research & Development registered a high of $203.7 million during FY2024, and its lowest value of $191.6 million during FY2023.
  • Its 2-year average for Research & Development is $197.7 million, with a median of $197.7 million in 2023.
  • Data for Inhibrx Biosciences' Research & Development shows a peak YoY grew of 6.32% (in 2024) over the last 5 years.
  • Over the past 2 years, Inhibrx Biosciences' Research & Development (Yearly) stood at $191.6 million in 2023, then grew by 6.32% to $203.7 million in 2024.